"John Tishman is a true pioneer in the Construction Management industry. Through his CM leadership, some of America's most well-known buildings have been brought to successful completion."
---Bruce D'Agostino, president and chief executive, Construction Management Association of America
"Building Tall will provide readers with insights into John Tishman's career as a visionary engineer, landmark builder, and great businessman. Responsible for some of the construction world's most magnificent projects, John is one of the preeminent alumni in the history of Michigan Engineering. His perspectives have helped me throughout my time as dean, and his impact will influence generations of Construction Management professionals and students."
---David C. Munson, Jr., Robert J. Vlasic Dean of Engineering, University of Michigan
In this memoir, University of Michigan graduate John L. Tishman recounts the experiences and rationale that led him to create the entirely new profession now recognized and practiced as Construction Management. It evolved from his work as the construction lead of the "owner/builder" firm Tishman Realty and Construction, and his personal role as hands-on Construction Manager in the building of an astonishing array of what were at the time the world's tallest and most complex projects. These include
The world's first three 100-story towers---the original "twin towers" of the World Trade Center in Manhattan and the Hancock Tower in Chicago. The Epcot Center at Disney World. The Renaissance Center in Detroit. New York's Madison Square Garden.
Tishman interweaves the stories behind the construction of these and many other important buildings and projects with personal reminiscences of his dealings with Henry Ford, Jr., Disney's Michael Eisner, casino magnate Steve Wynn, and many others into a practical history of the field of Construction Management, which he pioneered.
This book will be of interest not only to a general public interested in the stories and personalities behind many of the most iconic construction projects of the post–World War II period in the United States but to students of engineering and architecture and members of the new field of Construction Management.
Cost, expected benefits, and risks are paramount in grant agencies' decisions to fund scientific research. In Cognitive Economy, Nicholas Rescher outlines a general theory for the cost-effective use of intellectual resources, amplifying the theories of Charles Sanders Pierce, who stressed an “economy of research.” Rescher discusses the requirements of cooperation, communication, cognitive importance, cognitive economy, as well as the economic factors bearing on induction and simplicity. He then applies his model to several case studies and to clarifying the limits imposed on science by economic considerations.
Cost-benefit analysis is a widely used governmental evaluation tool, though academics remain skeptical. This volume gathers prominent contributors from law, economics, and philosophy for discussion of cost-benefit analysis, specifically its moral foundations, applications and limitations.
This new scholarly debate includes not only economists, but also contributors from philosophy, cognitive psychology, legal studies, and public policy who can further illuminate the justification and moral implications of this method and specify alternative measures.
These articles originally appeared in the Journal of Legal Studies.
- Matthew D. Adler - Gary S. Becker
- John Broome - Robert H. Frank
- Robert W. Hahn - Lewis A. Kornhauser
- Martha C. Nussbaum - Eric A. Posner
- Richard A. Posner - Henry S. Richardson
- Amartya Sen - Cass R. Sunstein
- W. Kip Viscusi
With budgets squeezed at every level of government, cost-benefit analysis (CBA) holds outstanding potential for assessing the efficiency of many programs. In this first book to address the application of CBA to social policy, experts examine ten of the most important policy domains: early childhood development, elementary and secondary schools, health care for the disadvantaged, mental illness, substance abuse and addiction, juvenile crime, prisoner reentry programs, housing assistance, work-incentive programs for the unemployed and employers, and welfare-to-work interventions. Each contributor discusses the applicability of CBA to actual programs, describing both proven and promising examples.
The editors provide an introduction to cost-benefit analysis, assess the programs described, and propose a research agenda for promoting its more widespread application in social policy. Investing in the Disadvantaged considers how to face America’s most urgent social needs with shrinking resources, showing how CBA can be used to inform policy choices that produce social value.
A growing number of archaeologists are applying Geographic Information Science (GIS) technologies to their research problems and questions. Advances in GIS and its use across disciplines allows for collaboration and enables archaeologists to ask ever more sophisticated questions and develop increasingly elaborate models on numerous aspects of past human behavior. Least cost analysis (LCA) is one such avenue of inquiry. While least cost studies are not new to the social sciences in general, LCA is relatively new to archaeology; until now, there has been no systematic exploration of its use within the field.
This edited volume presents a series of case studies illustrating the intersection of archaeology and LCA modeling at the practical, methodological, and theoretical levels. Designed to be a guidebook for archaeologists interested in using LCA in their own research, it presents a wide cross-section of practical examples for both novices and experts. The contributors to the volume showcase the richness and diversity of LCA’s application to archaeological questions, demonstrate that even simple applications can be used to explore sophisticated research questions, and highlight the challenges that come with injecting geospatial technologies into the archaeological research process.
In 1998, health expenditures in the United States accounted for 12.9% of national income-the highest share of income devoted to health in the developed world. The United States also spends more on medical research than any other country-in 2000, the federal government dedicated $18.4 billion to it, compared with only $3.7 billion for the entire European Union. In this book, leading health economists ask whether we are getting our money's worth.
From an economic perspective, they find, the answer is a resounding "yes": in fact, considering the extraordinary value of improvements to health, we may even be spending too little on medical research. The evidence these papers present and the conclusions they reach are both surprising and convincing: that growth in longevity since 1950 has been as valuable as growth in all other forms of consumption combined; that medical advances producing 10% reductions in mortality from cancer and heart disease alone would add roughly $10 trillion-a year's GDP-to the national wealth; or that the average new drug approved by the FDA yields benefits worth many times its cost of development.
The papers in this book are packed with these and many other surprising revelations, their sophisticated analysis persuasively demonstrating the massive economic benefits we can gain from investments in medical research. For anyone concerned about the cost and the value of such research-from policy makers to health care professionals and economists-this will be a landmark book.
Medical Care Output and Productivity
Edited by David M. Cutler and Ernst R. Berndt University of Chicago Press, 2001 Library of Congress RA410.5.M425 2001 | Dewey Decimal 338.433621
With the United States and other developed nations spending as much as 14 percent of their GDP on medical care, economists and policy analysts are asking what these countries are getting in return. Yet it remains frustrating and difficult to measure the productivity of the medical care service industries.
This volume takes aim at that problem, while taking stock of where we are in our attempts to solve it. Much of this analysis focuses on the capacity to measure the value of technological change and other health care innovations. A key finding suggests that growth in health care spending has coincided with an increase in products and services that together reduce mortality rates and promote additional health gains. Concerns over the apparent increase in unit prices of medical care may thus understate positive impacts on consumer welfare. When appropriately adjusted for such quality improvements, health care prices may actually have fallen. Provocative and compelling, this volume not only clarifies one of the more nebulous issues in health care analysis, but in so doing addresses an area of pressing public policy concern.
“Cost-benefit analysis” is a term that is used so frequently we rarely stop to think about it. But relying on it can lead to some dubious conclusions, as Frank Ackerman points out in this eye-opening book. For example, some economists have argued that states should encourage—and even subsidize—cigarette smoking by citizens because smoking will shorten life spans and therefore reduce the need and expense of caring for the elderly. How did the economists reach that conclusion? The answer is cost-benefit analysis, Ackerman explains.
Then in clear, understandable language, he describes an alternative, precautionary approach to making decisions under uncertainty. Once a mere theory, the precautionary principle has now been applied in practice through the European Union’s REACH protocol. Citing major studies, many of which he has directed, he shows that the precautionary approach has not only worked, but has been relatively cheap.
Poisoned for Pennies shows how the misuse of cost-benefit analysis is impeding efforts to clean up and protect our environment, especially in the case of toxic chemicals. According to Ackerman, conservatives—in elected office, in state and federal regulatory agencies, and in businesses of every size—have been able to successfully argue that environmental clean-up and protection are simply too expensive. But he proves, that is untrue in case after case.
Ackerman is already well known for his carefully reasoned attacks on the conventional wisdom about the costs of environmental regulation. This new book, which finds Ackerman ranging from psychological research to risk analysis to the benefits of aggressive pesticide regulation, and from mad cow disease to lead paint, will further his reputation as a thought leader in environmental protection. We can’t afford not to listen to him.
Averch describes and analyzes common strategies for solving problems in public policy. The strategies discussed include the use of markets, bureaus, regulation, planning and budgeting, benefit-cost, systems analysis, and evaluation. He examines the historical development of each strategy; describes how each strategy would ideally work; explains the necessary or sufficient conditions that permit each strategy to work; lists the potential failures of each strategy; and provides a judgment or appraisal of each strategy.
New medical technologies are a leading driver of U.S. health care spending. This report identifies promising policy options to change which medical technologies are created, with two related policy goals: (1) Reduce total health care spending with the smallest possible loss of health benefits, and (2) ensure that new medical products that increase spending are accompanied by health benefits that are worth the spending increases.
How much should citizens invest in promoting health, and how should resources be allocated to cover the costs? A major contribution to economic approaches to the value of health, this volume brings together classic and up-to-date research by economists and public health experts on theories and measurements of health values, providing useful information for shaping public policy.